vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $182.4M, roughly 1.6× Climb Global Solutions, Inc.). Bio-Techne runs the higher net margin — 12.8% vs 1.8%, a 11.0% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs -6.4%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 4.2%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CLMB vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $295.9M |
| Net Profit | $3.3M | $38.0M |
| Gross Margin | 14.5% | 64.6% |
| Operating Margin | 2.1% | 18.4% |
| Net Margin | 1.8% | 12.8% |
| Revenue YoY | 32.1% | -6.4% |
| Net Profit YoY | -9.5% | 68.3% |
| EPS (diluted) | $0.18 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $295.9M | ||
| Q3 25 | $161.3M | — | ||
| Q2 25 | $159.3M | $317.0M | ||
| Q1 25 | $138.0M | $316.2M | ||
| Q4 24 | $161.8M | $297.0M | ||
| Q3 24 | $119.3M | $289.5M | ||
| Q2 24 | $92.1M | $306.1M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $38.0M | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $6.0M | $-17.7M | ||
| Q1 25 | $3.7M | $22.6M | ||
| Q4 24 | $7.0M | $34.9M | ||
| Q3 24 | $5.5M | $33.6M | ||
| Q2 24 | $3.4M | $40.6M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 64.6% | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 16.5% | 62.7% | ||
| Q1 25 | 16.9% | 67.9% | ||
| Q4 24 | 19.3% | 65.3% | ||
| Q3 24 | 20.3% | 63.2% | ||
| Q2 24 | 20.2% | 66.4% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 18.4% | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 5.0% | -7.5% | ||
| Q1 25 | 3.5% | 12.2% | ||
| Q4 24 | 7.2% | 16.0% | ||
| Q3 24 | 7.1% | 13.8% | ||
| Q2 24 | 4.6% | 15.0% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 12.8% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 3.7% | -5.6% | ||
| Q1 25 | 2.7% | 7.1% | ||
| Q4 24 | 4.3% | 11.7% | ||
| Q3 24 | 4.6% | 11.6% | ||
| Q2 24 | 3.7% | 13.3% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.24 | ||
| Q3 25 | $1.02 | — | ||
| Q2 25 | $1.30 | $-0.11 | ||
| Q1 25 | $0.81 | $0.14 | ||
| Q4 24 | $1.52 | $0.22 | ||
| Q3 24 | $1.19 | $0.21 | ||
| Q2 24 | $0.75 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $118.4M | $2.0B |
| Total Assets | $458.8M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $172.9M | ||
| Q3 25 | $49.8M | — | ||
| Q2 25 | $28.6M | $162.2M | ||
| Q1 25 | $32.5M | $140.7M | ||
| Q4 24 | $29.8M | $177.5M | ||
| Q3 24 | $22.1M | $187.5M | ||
| Q2 24 | $48.4M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $2.0B | ||
| Q3 25 | $109.3M | — | ||
| Q2 25 | $105.2M | $1.9B | ||
| Q1 25 | $95.6M | $2.0B | ||
| Q4 24 | $90.6M | $2.1B | ||
| Q3 24 | $87.7M | $2.1B | ||
| Q2 24 | $79.8M | $2.1B |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $2.5B | ||
| Q3 25 | $376.1M | — | ||
| Q2 25 | $420.7M | $2.6B | ||
| Q1 25 | $370.1M | $2.6B | ||
| Q4 24 | $469.2M | $2.7B | ||
| Q3 24 | $371.9M | $2.7B | ||
| Q2 24 | $302.8M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
